Brief: Iveric Bio Inc - Submitted To FDA Second Part Of NDA For Avacincaptad Pegol For Treatment Of Ga Secondary To Age-Related Macular Degeneration

IVERIC bio

28/11/2022 13:12

Nov 28 (Reuters) - Iveric Bio Inc  ISEE.O :
    * IVERIC BIO INC - SUBMITTED TO FDA SECOND PART OF NDA FOR
AVACINCAPTAD PEGOL FOR TREATMENT OF GA SECONDARY TO AGE-RELATED
MACULAR DEGENERATION
    * IVERIC BIO INC -  REMAINS ON TRACK TO COMPLETE SUBMISSION
OF NDA
TO FDA BY END OF 2022
    * IVERIC BIO - BASED ON FORMAL FEEDBACK FROM FDA, CO INTENDS
TO
PURSUE FURTHER DISCUSSIONS WITH FDA ABOUT UTILIZING GATHER1,
GATHER2 CLINICAL TRIAL DATA
    * IVERIC BIO - AS RESULT OF THESE ONGOING DISCUSSIONS, CO
DOES NOT
BELIEVE IT NEEDS TO CONDUCT NEW CLINICAL TRIAL OF ACP IN
PATIENTS WITH IAMD

Further company coverage:  ISEE.O 
 ((Reuters.Briefs@thomsonreuters.com;;))